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Abstract
Background: The aim of this population-based study was to assess independent prognostic factors in ovarian
cancer using relative survival (RS) and to investigate changes in RS rates from 1982 to 2005.
Methods: Data on 748 patients with ovarian cancer were provided by the Côte d’Or gynaecologic cancer registry.
The RS was estimated using a generalized linear model with a Poisson error structure. Relative survival and its 95%
confidence interval (CI) were described at the following specific time points 1, 3 and 5 years. The effect of
prognostic factors on survival was assessed with multivariate analyses of RS.
Results: The median follow-up was 12 years. The RS rates at 1, 3 and 5 years were 81%, 55% and 44%,
respectively. As compared with the period 1982-1989, an improvement in survival was found for the period 1998-
2005: HR = 0.52[0.40-0.67]. Women who lived in urban areas had better RS: HR = 0.82[0.67-0.99]. Patients with
epithelial types of ovarian cancer other than mucinous or endometrioid cancer had worse RS than those with
serous histology. Age ≥ 70 years was associated with lower survival.
Conclusions: Period of diagnosis, stage at diagnosis, histology, place of residence and age were independent
prognostic factors for survival in ovarian cancer. An improvement in the survival rate was observed after 1998 but a
significant improvement was limited to advanced stage cancers.
Background
Ovarian cancer is the sixth most common cancer in
women. Incidence rates are highest in developed coun-
tries [1]. In France, ovarian cancer accounted for 4375
new cases and 3180 deaths in 2005 [2].
Despite improved knowledge of prognostic factors and
advances in treatments for ovarian cancer, the outcome
in terms of long-term survival remains unknown. In fact,
while some studies [3,4] showed a significant increase in
the survival rate over time, others showed similar survival
rates over time [5]. Moreover, many previous studies on
prognostic factors and survival in ovarian cancer were
based on selected patients, and did not use relative survi-
val (RS) as the primary end-point [4,6-8].
T oo u rk n o w l e d g e ,n op o p u l a t i o n - b a s e ds t u d yh a s
used RS as the primary end-point to determine indepen-
dent prognostic factors in ovarian cancer. Relative survi-
val is an estimator of the excess mortality ratio. The use
of RS could make it possible to correct indirectly for
deaths not attributable to ovarian cancer [9].
The Côte d’Or gynaecologic cancer registry is the only
cancer registry in France that focuses on gynaecologic
cancers. It has been collecting comprehensive popula-
tion-based data since 1982.
Our purpose was to study relative survival according
to the main patient and tumour characteristics.
Methods
Population
Patients with ovarian cancer were identified from the
Côte d’Or gynaecologic cancer registry. This study
included all patients diagnosed with primary ovarian
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approval from the national ethics committee (Commis-
sion Nationale de l’Informatique et des Libertés) was
obtained for the Côte d’Or gynaecologic cancer registry,
which allowed the use of data recorded in this registry
for medical studies. Writteni n f o r m e dc o n s e n tw a sa l s o
obtained from every participant at their first medical
examination.
Studied variables and endpoints
Demographic data obtained from each patient’sm e d i c a l
records included age at diagnosis and menopausal sta-
tus. The town of residence was also known for each
patient and was defined as a rural or urban area using
data provided by the National Institute for Statistics and
Economic Studies (INSEE) of France. We also obtained
clinical data on the histological type and the surgical
stage according to the International Federation of Gyne-
cology and Obstetrics (FIGO) system; staging was based
on clinical information when the surgical stage was not
available. Patients were categorised into three age
groups: < 50 years, 50-70 years, and ≥ 70 years. For the
histological type, cases were divided into four groups:
serous, mucinous and endometrioid, other epithelial
types and non-epithelial tumours. The majority of the
other-epithelial group were clear cell tumours and
unspecified adenocarcinomas, whereas the non-epithelial
group included germ cell and sex-cord stromal tumours.
Years of diagnosis were grouped into 3 periods: 1982-
1989, 1990-1997 and 1998-2005.
Survival was estimated from the date of diagnosis until
the date of death (all causes). Patients who were alive at
the cut-off date or died after the cut-off date (01 January
2009) were censored.
Statistical methods
Continuous variables are described as means, standard
deviations (SD), and medians, and qualitative variables are
given as percentages. The percentage of missing values is
also provided. Follow- up was calculated using the reverse
Kaplan Meier method which is calculated in the same way
as the Kaplan-Meier estimate of survival function, but
with the meaning of the status indicators reversed [10].
Relative survival (RS) is the ratio between the observed
survival rate in the patient group and the expected sur-
vival rate of a comparable group from the general popu-
lation of the same age, sex and year of diagnosis.
Relative survival represents an estimation of survival
eliminating the effect of competing causes of death.
Annual mortality rates for the entire female population
of Côte d’Or stratified by age and calendar time were
used to calculate expected survival. The RS was esti-
mated using a generalized linear model with a Poisson
error structure [9].
Relative survival and its 95% confidence interval (CI)
were described at the following specific time points 1, 3
and 5 years. Univariate and multivariate relative survival
analyses were performed to determine independent
prognostic factors in ovarian cancer. Five-year RS esti-
mates and their 95% CIs were calculated for variables of
interest across the study periods and according to the
stage of diagnosis.
All tests were two-tailed and the level of p < 0.05 was
considered statistically significant. Analyses were per-
formed using Statistical Analysis Software version 9.1
and STATA (version 10).
Results
Population
A total of 808 women were diagnosed with ovarian car-
cinoma from 1982 to 2005. Among them, 60 were lost
to follow-up at the date of diagnosis. Thus, a total of
748 were retained for the study. The demographic and
clinical characteristics of the study population are pro-
vided in Table 1 and the distribution of these factors
over the study periods is shown in Table 2. The median
age at diagnosis was 62 years (range, 11 to 94 years) and
the mean age was 61 years (SD = 14.8). Tumour charac-
teristics did not vary, on the whole, over the three peri-
ods. However, there was a slight increase in the
proportion of patients with stage III disease even though
this was not statistically significant (Table 2).
Relative survival
Median follow up was 11.9 years (range 0.003 to 26
years). At the cut-off date, 516 (69%) patients had died
and 56 (7%) were lost to follow-up. The median survival
time was 40 months. The RS rates at 1, 3, and 5 years
for all patients were respectively 81%, 55% and 44% (Fig-
ure1). Table 3 shows RS rates based on patient and
tumour characteristics. Five-year RS rates per stage I, II,
III and IV were 85%, 48%, 29% and 14%, respectively.
Univariate hazard ratios (Table 3) were 4.51[2.69-7.57],
7.99[5.34-11.96] and 12.83[8.18-20.08], for stage II, III
and IV, respectively, as compared to stage I. When
divided according to age-group < 50 years, 50-70 years
and ≥ 70 years, 5-year RS rates were 58%, 43% and 32%,
respectively and univariate hazard ratios were 1.51[1.16-
1.95] and 2.23[1.78-2.93], respectively, as compared to
age-group < 50 years. After dividing our study popula-
tion into early stage (stage FIGO I and II) and advanced
stage disease, table 4 shows that, after controlling for
stage, patients aged over 70 years had worse relative sur-
vival rates as compared to younger patients (< 50 years)
in both the advanced and early-stage group.
Five-year RS was 41% for serous, 31% for other epithe-
lial tumours: HR = 1.37[1.04-1.82], 49% for mucinous
and endometrioid: HR = 0.74[0.58-0.96] and 63% for
Hamidou et al. BMC Cancer 2010, 10:622
http://www.biomedcentral.com/1471-2407/10/622
Page 2 of 8non epithelial cancers: HR = 0.53[0.33-0.84]. Women
who lived in urban areas had a better 5-year RS rate
compared to those who lived in rural areas: 46% vs. 40%
(HR = 0.81[0.67-0.99]).
Multivariate analyses
Multivariate analyses of RS confirmed that age (p =
0.003), FIGO stage (p < 0.0001), histological type (p =
0.01), place of residence (p = 0.04) and period of diag-
nosis (p < 0.0001) were independent prognostic factors
for RS in ovarian cancer. As compared to age younger
than 50 years, age older than 70 years was associated
with lower survival HR = 1.60 [1.21-2.12]. An increased
risk of death was also observed with advanced stage as
compared to stage I with HR = 4.43 [2.63-7.46], HR =
8.80 [5.81-13.34] and HR = 13.07 [8.26-20.66] for FIGO
II, III and IV, respectively. As compared to serous type,
other epithelial tumours apart from mucinous and endo-
metrioid were associated with lower survival: HR = 1.62
[1.22-2.16]. As compared to women who lived in rural
areas, women who lived in urban areas had better survi-
val HR 0.82[0.67-0.99] (Table 3).
Changes in the survival rate over time
During the periods 1982-1989 and 1998-2005, women
diagnosed with ovarian cancer had an improvement in
5-year RS rates from 41% to 49%; but no difference in
the survival rate was found between the periods 1982-
1989 and 1990-1997. Therefore, these two periods were
combined for the rest of the analyses. To describe the
improvement according to variables of interest over
time, RS from 1982 to 1997 was compared with that
from 1998 to 2005 (table 5). After dividing our study
population into early (stage I-II) and advanced (stage
III-IV) stage disease, the improvement seemed to be
more pronounced in advanced stage (20% to 36%) and
in younger and middle-aged patients.
Discussion
Our study included all cases of invasive ovarian cancer
diagnosed between 1982 and 2005 in a well-defined
population using a cancer registry specialized in ovarian
cancer.
The results of our study showed a progressive decline
in the survival rate with 3-year and 5-year RS rates of
55% and 44%, respectively. These results are in agree-
ment with those reported in western Sweden [11] where
the 5-year RS rate for patients diagnosed with ovarian
cancer from 1993 to 1998 was 46%. In the same way, a
population-based study in Germany [12] showed a 5-
year RS rate of 45% among patients with ovarian cancer,
diagnosed from 1999 to 2003.
In line with the present study, many studies on ovar-
ian cancer found age to be an independent prognostic
factor [7,11,13-16]. It is important to emphasize that
our analysis was based on a population-based cohort
and that it is, to our knowledge, the only one to assess
independent prognostic factors in ovarian cancer using
RS as the primary end-point. In our study, women aged
younger than 50 years had the best prognosis of all age
groups. Multivariate relative analyses showed that only
patients aged older than 70 years had significantly worse
survival as compared to those younger than 50 years.
This can be due to the particular management of
Table 1 Patients and tumour characteristics
Variables Median Range
Age (years) 62 11-94
Follow-up (years) 11.9 0.003-26.08
Number of patients %
Age
< 50 154 20.6
50-70 359 48.0
≥ 70 235 31.4
Stage at diagnosis
I 186 24.8
II 60 8.0
III 387 51.7
IV 90 12.0
Unknown 25 3.3
Histological type
Serous 433 58.0
Mucinous 77 10.3
Endometrioid 90 12.0
Clear cell 40 5.3
Adenocarcinoma unspecified 46 6.1
Other epithelial 5 0.6
Sex-cord stromal 30 4.0
Germ cell 27 3.6
Period of diagnosis
1982-1989 221 29.5
1990-1997 255 34.1
1998-2005 272 36.4
Place of residence
Urban 412 55.2
Rural 335 44.7
Unknown 1 0.1
Menopause
Yes 450 60.2
No 138 18.4
Unknown 160 21.4
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1982-1989 1990-1997 1998-2005
Variables Number of patients (%) Number of patients (%) Number of patients (%) Fisher p
N = 221 N = 255 N = 272
Age 0.722
< 50 44(19.9%) 59 (23.1%) 51(18.7%)
50-70 110(49.7%) 119(46.7%) 130(47.8%)
≥ 70 67(30.3%) 77(30.2%) 91(33.5%)
Stage at diagnosis 0.091
I 66(29.8%) 58(22.7%) 62(22.8%)
II 18(8.1%) 27(10.6%) 15(5.5%)
III 97(43.9%) 134(52.5%) 156(57.3%)
IV 29(13.1%) 30(11.8%) 31(11.4%)
Unknown 11(4.9%) 6(2.3%) 8(3.0%)
Histological type
Serous 122(55.2%) 157(61.6%) 154(56.6%) 0.178
Mucinous Endometrioid 51(23.0%) 50(19.6%) 66(24.2%)
Other epithelial 28(12.7%) 36(14.1%) 27(10.0%)
Non epithelial 20(9.0%) 12(4.7%) 25(9.1%)
Place of residence
Urban 126(57.0%) 138(54.1%) 148(54.4%) 0.803
Rural 95(42.9%) 116(45.5%) 124(45.6%)
Unknown 1(0.4%)
Menopause
Yes 160(72.4%) 182(71.4%) 108(39.7%) 0.570
No 43(19.5%) 57(22.3%) 38(14.0%)
Unknown 18(8.1%) 16(6.3%) 126(46.3%)
Figure 1 Relative survival of the study population.
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receive standard combination therapy [17,18], and thus
benefit less from advances in treatment.
As in other studies [11,13-16,19], the results of the
present study showed clearly that survival is stage-
dependent. In fact, multivariate analyses showed that
the FIGO stage was the most powerful prognostic factor,
with a hazard ratio of 13 in stage IV in the multivariate
analysis. In our study, we found 5-year RS rates of 85%,
48%, 29% and 14% for stages I, II, III and IV, respec-
tively. This could be compared with the findings
obtained from the SEER program which showed 5-year
RS rates of 88.3%, 65.0%, 34.1% and 19.7%, respectively
for patients with stage I, II, III and IV ovarian cancer
diagnosed between 1988 and 2001[16]. The results were
closer for stage I, III and IV, but a considerably lower
survival rate was recorded in our sample for stage II dis-
ease. This difference concerning stage II may be
explained by disparities in the proportion of patients
who did not receive optimal debulking and were thereby
understaged. It is worth noting that recent studies
[ 2 0 , 2 1 ]s h o w e dt h a tal a r g en u m b e ro fo v a r i a nc a n c e r
patients with clinically localized disease still underwent
incomplete surgical staging.
Unlike some studies [11,13] the result of the present
study found histological subtype to be an independent
prognostic factor in ovarian cancer. Our results showed
that patients with non-epithelial or endometrioid-muci-
nous tumours had better survival as compared to those
with serous tumours in univariate analyses of RS but not
in the multivariate analyses. Moreover, patients with other
epithelial subtypes, mainly clear cell and unspecified
Table 3 Relative survival according to patient and tumour characteristics: Univariate and multivariate analyses
Relative survival Univariate analysis
N = 748
Multivariate analysis
N = 722
Variables Patients
at risk
Number
of deaths
1-year
RS (CI)
3-year RS (CI) 5-year
RS (CI)
HR 95% CI P value HR 95% CI P value
Age < 0.0001 0.003
< 50 154 79 89 (82.7-93.0) 68 (60.4-75.3) 58 (50.0-65.9) 1 1
50-70 359 243 84 (79.6-87.4) 55 (50.8-60.6) 43 (37.8-48.5) 1.51 1.16-1.95 < 0.0001 1.22 0.94-1.59 0.12
≥ 70 235 194 70 (63.4-76.0) 42 (35.2-49.2) 32 (24.9-38.7) 2.23 1.78-2.93 0.001 1.60 1.21-2.12 0.0009
Stage at
diagnosis
< 0.0001 < 0.0001
I 186 58 98 (93.9-99.3) 89 (82.7-93.1) 85 (78.1-90.0) 1 1
II 60 44 82 (68.4-89.8) 60.3 (45.9-72.1) 48 (34.5-61.0) 4.51 2.69-7.57 < 0.0001 4.43 2.63-7.46 < 0.0001
III 387 320 78 (73.5-82.0) 44 (38.8-49.1) 29 (24.0-33.6) 7.99 5.34-11.96 < 0.0001 8.80 5.81-13.34 < 0.0001
IV 90 78 62 (50.5-71.1) 28 (18.6-37.8) 14 (6.7-22.7) 12.82 8.18-20.08 < 0.0001 13.07 8.26-20.66 < 0.0001
Unknown 25 16
Histological type 0.0001 0.010
Serous 433 309 84 (80.4-87.7) 56(50.8-60.7) 41 (36.3-46.3) 1 1
Mucinous-
Endometrioid
167 105 82(75.3-87.4) 56 (48.1-63.7) 49 (40.8-56.9) 0.74 0.58-0.96 0.022 1.23 0.95-1.58 0.11
Other
epithelial
91 73 65 (54.4-74.4) 40 (29.2-49.8) 31 (21.0-41.2) 1.37 1.04-1.82 0.023 1.62 1.22-2.16 0.0008
Non epithelial 57 29 78 (63.6-87.5) 67 (50.6-78.6) 63 (46.8-75.1) 0.53 0.33-0.84 0.007 1.19 0.72-1.96 0.47
Period of
diagnosis
0.0004 0.0001
1982-1989 221 159 82 (75.8-86.6) 49 (42.0-56.0) 41 (34.2-48.2) 1 1
1990-1997 255 191 74 (68.1-79.3) 50 (43.4-56.3) 39 (32.8-45.6) 1.07 0.86-1.34 0.5217 0.96 0.77-1.21 0.79
1998-2005 272 166 87 (82.2-90.8) 64 (57.2-69.3) 49 (42.5-55.5) 0.67 0.52-0.87 0.002 0.52 0.40-0.67 < 0.0001
Place of
residence
Rural 335 242 79 (74.0-83.2) 40 (34.7-46.0) 40 (34.7-46.0) 1 1
Urban 412 273 83 (78.6-86.4) 46 (40.6-51.1) 46 (40.6-51.1) 0.81 0.67-0.99 0.04 0.82 0.67-0.99 0.04
Unknown 1 1
Menopause
Yes 450 346 78 (74.1-82.2) 49 (43.8-53.6) 36 (31.4-41.0) 1
No 138 72 88 (81.0-92.5) 70 (60.8-76.7) 60 (50.8-67.7) 1.93 1.48-2.51 < 0.0001
Unknown 160 98 83 (75.6-88.0) 58 (49.4-65.5) 49 (40.2-57.0)
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val as compared to those with serous tumours. Clear cell
histology is generally accepted as an unfavourable histol-
ogy, but the results concerning other histology subtypes
are contradictory. In a recent study [14] comparing the
survival of women with clear cell versus other epithelial
ovarian cancers, clear cell had poorer overall survival. In a
recent review [7], clear cell histology and mucinous can-
cers were associated with worse survival. In contrast, an
Australian study [15] found that endometrioid and non-
epithelial tumours were associated with better survival as
compared with serous tumours, while non-specified ade-
nocarcinoma correlated with worse survival.
In multivariate analyses, the place of residence was an
independent prognostic factor for relative survival in ovar-
ian cancer. Women who lived in rural areas had a greater
excess risk of death due to ovarian cancer than did those
who lived in urban areas. This may be due to more
restricted access to high performance treatment facilities
in these regions. The results of the multivariate model
suggest that differences in stage distribution (that women
in rural areas may be diagnosed at a later stage) do not
explain the poorer survival in rural areas, as the hazard
ratio remained unchanged in the multivariate model.
In our study, we found the period of diagnosis to be
an important independent prognostic factor. Patients
diagnosed during the period 1998-2005 had significantly
better survival as compared to those diagnosed during
the period 1982-1989, whereas no difference in survival
was found for women diagnosed in the period 1990-
1997. Similar results were found by Engel et al in a
population-based cohort of ovarian cancer patients dur-
ing 1978-1997. This study [5] found that survival rates
before and after 1988 were similar.
During the study period, we found an improvement in
RS in women with early stage as well as in those with
advanced stage ovarian cancer, but the improvement
was more pronounced for women with advanced stages
(Table 5). This may be explained by the importance of
maximal cytoreduction in the recent period and by the
fact that the workup and staging are more comprehen-
sive. In fact, in our study, the proportion of FIGO stage
III was higher in the most recent period compared to
the first period of diagnosis (Table 2). In the same way,
in their study [22], Chan et al showed a significant
improvement across time in the survival of women with
surgically stage III and IV diseases.
Table 4 Five-year relative survival rates according to the
stage of diagnosis
Variables N Deaths 5-year relative survival rates
(95% CI)
Age
FIGO I-II
< 50 73 20 80.69 (69.09-88.29)
50-70 111 40 79.50 (69.94-86.32)
>=70 61 42 59.88 (43.12-73.15)
FIGO III-IV
< 50 78 59 35.83 (25.11-46.65)
50-70 231 192 26.31 (20.59-32.36)
> = 70 155 137 20.70 (13.91-28.44)
Histologic type
FIGO I-II
Serous 101 44 73.38 (61.98-81.85)
Mucinous-
endometroîd
78 31 74.94 (62.74-83.65)
Other epithelials 34 19 65.82 (45.99-79.83)
Non epithelials 32 8 93.79 (67.65-98.95)
FIGO III-IV
Serous 315 255 31.11 (25.68-36.68)
Mucinous-
endometroîd
82 71 21.36 (12.94-31.19)
Other epithelials 49 48 6.21 (1.41-16.34)
Non epithelials * * *
Period of diagnosis
FIGO I-II
1982-1989 84 39 73.44 (61.20-82.35)
1990-1997 84 38 75.40 (63.00-84.15)
1998-2005 77 25 80.83 (67.98-88.93)
FIGO III-IV
1982-1989 122 110 19.46 (12.53-27.52)
1990-1997 160 145 20.31 (14.24-27.15)
1998-2005 182 133 36.24 (28.68-43.84)
Place of residence
FIGO I-II
Urban 143 59 75.02 (65.89-82.03)
rural 102 43 77.66 (67.08-85.20)
FIGO III-IV
Urban 248 203 28.54 (22.62-34.71)
rural 215 184 23.38 (17.63-29.63)
Table 5 Trends in 5-year relative survival rates over time
Variables 5-year relative survival (95%CI)
1982-1997 1998-2005
Age
< 50 55 (44.6-64.3) 65 (50.0-76.4)
50-70 38 (31.9-44.9) 52 (42.1-60.2)
≥ 70 31(22.2-39.8) 33 (22.0-44.8)
Stage at diagnosis
I-II 74 (66.1-80.9) 81 (68.0-89.0)
III-IV 20 (15.2-24.8) 36 (28.7-43.7)
Histological type
Serous 37 (31.0-43.1) 49 (40.4-57.9)
Non serous 40 (32.1-47.5) 49(39.0-58.3)
Place of residence
Urban 43 (36.3-49.2) 51 (42.1-59.9)
Rural 37 (29.9-43.7) 47 (37.0-56.0)
Hamidou et al. BMC Cancer 2010, 10:622
http://www.biomedcentral.com/1471-2407/10/622
Page 6 of 8The survival improvement appearing after 1998 may
be attributed to advances in treatment. Several studies
have explored the role of surgery in advanced ovarian
cancer [23]. Most of these studies supported the role of
tumour debulking as the best first-line treatment in
women with advanced ovarian cancer. It is also likely
that advances in chemotherapy as well as in general
medical support have contributed to this improvement.
The strength of the present study is that it includes all
patients with ovarian cancer diagnosed from 1982 to
2005 in a well-defined geographical area. Furthermore,
the follow up for vital status was nearly complete with a
low lost-to-follow-up rate (7%). With this large panel,
the results of our study could be considered representa-
tive of survival in French patients during this period.
Unlike clinical trials, in which patients are highly
selected, population-based survival studies are based on
heterogeneous groups and can be used to determine
prognostic factors in cancer, with little potential for
selection bias [24].
Conclusion
The results of this population-based study showed that
advanced age at diagnosis, advanced FIGO stage, period
of diagnosis, histological type and place of residence are
independent prognostic factors in ovarian cancer and
that long-term survival has improved over the last 10
years. Despite the overall improvement in ovarian can-
cer survival, novel treatment strategies are still
warranted.
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